ABIVAX Stock Continues Its Climb, Up 5.15% Over the Week
Biotech company Abivax has entered the latter half of the week in positive territory. The stock is up 2.45% this Wednesday, reaching a price of 83.70 euros. Over seven days, the stock has accelerated with a gain of 5.15%, while the CAC 40 has slightly declined by 0.19%. This upward trend comes in a context where the stock has shown an exceptional annual performance, exceeding 770%.
Significant Weekly Gains for French Biotech Stock
The stock of the French biotech company is gaining ground towards the end of the week. Priced at 83.70 euros this Wednesday, the stock has improved its position compared to Tuesday's close of 81.70 euros, marking a gain of 2.45%. Over the past seven days, Abivax has shown a much more substantial performance, with an increase of 5.15%. The momentum remains strongly positive over three months with a gain of 46.84%. Since the beginning of the year, the stock has accumulated a spectacular performance, exceeding 770%, which is significantly higher than the CAC 40's annual increase of 8.52%. However, it should be noted that traded volumes remain limited, with only 0.08% of capital being circulated. This characteristic is typical for small capitalizations, where portfolio rotations can more significantly impact the price movement. Last Monday, the stock recorded the highest rise in the SBF 120 with an increase of 3.03%.
Continued Revitalization of the Stock Amid Positive Developments
The revitalization of the stock follows a favorable period for the biotech. In early October, the publication of positive data from the ABTECT trial, which evaluates the drug candidate Obefazimod for the treatment of ulcerative colitis, supported the market's bullish tendencies. These results showed an encouraging tolerance profile. The volatility characteristic of the biotech sector is particularly evident in Abivax's profile. With a beta of 14.71, the stock shows a sensitivity to the index significantly higher than that of the market. Abivax's inclusion in the CAC Mid 60 and SBF 120 indices, decided during Euronext Paris's annual review in September, also improved the visibility of the stock among index managers and structured investors.
Technical Perspective: Stock Nears Short-Term Resistance Threshold
From a technical standpoint, the stock is approaching its short-term resistance threshold set at 83.60 euros, while the support threshold is at 69.40 euros. The 50-day moving average is at 73.13 euros, and the 200-day moving average at 28.30 euros: the stock is trading well above these benchmarks, illustrating the strength of the recent momentum. The Relative Strength Index (RSI) is at 62, an intermediate position that allows for movement in both directions. The MACD shows moderate progress, with a line at 1.94 and a signal line at 1.87. The Bollinger Bands delineate a trading zone between 70.52 and 85.70 euros, while the Average True Range (ATR) stands at 1.63 euros, reflecting the stock's intra-day volatility.
